Semaglutide has approvals for reducing cardiovascular risks in patients with heart disease, protecting kidney function in those with chronic kidney disease, and treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis
Notably, the risk appeared higher in trials studying weight loss indications, with higher doses, and with longer duration of treatment
Archived from the original on 2 February 2025
Curr Heart Fail Rep 6:272280
The molecular defect leading to fabry disease: Structure of human -galactosidase
A Program Built on Medical Safety, Evidence-Based Evaluation, and Ongoing Monitoring Why Safety Matters in Medical Weight Loss Safety is the foundation of the Medical Weight Loss and GLP-1 Treatment Program